{
  "docId": "019de070-e903-74a9-9f33-ed76332a0b3c",
  "docSlug": "2d6e5497feb9d00bbad6c284998b10c3",
  "documentTitle": "MindMed | Investor Presentation Deck | 33 slides",
  "authorId": "mindmed",
  "authorName": "MindMed",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 33,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "Includes headshots of Dr. Peter Gasser and Dr. Matthias Liechti. Mentions specific cost and time savings based on industry averages.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-e903-74a9-9f33-ed76332a0b3c/12",
  "deckHref": "/decks/019de070-e903-74a9-9f33-ed76332a0b3c",
  "deckJsonHref": "/decks/019de070-e903-74a9-9f33-ed76332a0b3c.json",
  "deckAnchorHref": "/decks/019de070-e903-74a9-9f33-ed76332a0b3c#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.15,
        "y": 0.6
      },
      "kind": "chart",
      "text": "Cost and time savings visualization",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "50857fe9-90c2-4039-a145-6a6159c4b2ac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.84,
        "x": 0.08,
        "y": 0.45
      },
      "kind": "diagram",
      "text": "Clinical trial development timeline from Pre-Discovery to Phase 3",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "55f771fe-7112-4054-95f7-cb2f1c40c05d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.1,
        "x": 0.22,
        "y": 0.35
      },
      "kind": "image",
      "text": "Dr. Peter Gasser & Dr. Matthias Liechti",
      "attrs": null,
      "subkind": "headshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "08e42ae1-78ff-412d-b55d-aa1abfda68b0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.13,
        "y": 0.72
      },
      "kind": "paragraph",
      "text": "Based on industry averages, this saves roughly $8.4 to $26.2 million in non-dilutive financing costs and 4+ years of time",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9a6bf389-927e-40af-bcdc-3a3434d816c7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.63,
        "y": 0.68
      },
      "kind": "paragraph",
      "text": "Currently preparing to open the IND with a Phase 2 Study. Plan to file IND Q3 2021",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6d2adc0-5f00-4431-8a95-4e0b15ca14b6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "MindMed Acquired Phase 2 Trial, Now Advancing as Phase 2b With FDA",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c79527e6-5a96-4c75-b3cb-69d4d3e55155",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.7,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "title",
      "text": "Using Phase 2 Trial To Jumpstart a Potential Phase 2b LSD Trial For Anxiety Disorder Est. Q4 2021",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "27a1591a-d877-47cd-85a3-63bd23e1d27b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "e090c24b-62d7-431a-b19b-5cd6834c2203",
      "evidence": "paragraph/paragraph: Based on industry averages, this saves roughly $8.4 to $26.2 million in non-dilutive financing costs and 4+ years of time",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "bb6eee49-bd3c-4451-8320-a8d0596f4bd4",
      "evidence": "Visual representation of clinical trial phases over time",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}